---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000014"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:21:37.414540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%

## Summary
- Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.
- Cash and marketable securities $609.6M as of Nov 30, 2024, up from $295.3M a year earlier.
- NX-5948 achieved 75.5% objective response rate in r/r CLL/SLL; received FDA Fast Track and EMA PRIME designations.
- Appointed John Northcott as Chief Commercial Officer in January 2025.
- Plans to commence registration trials for NX-5948 in CLL and explore autoimmune indications in 2025.

## SEC filing metadata
- accession: 0001549595-25-000014
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/0001549595-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/nrix-20250128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000014
- JSON: https://secwatch.observer/filing/0001549595-25-000014.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.